Cellentia

Cellentia focuses on developing drugs against metastatic cancers.

We have several collaborations ongoing.

Poor success rate of oncology drug development and most cancer-related deaths are due to metastatic cancers

We have an innovative platform to enable drug screening against metastatic cancer-like organoids with real-world patient diversity

We are identifying novel drugs to combat metastatic cancers and plan to sell early-stage assets to fund subsequent drug development. Over the next 2-3 years, we will also generate revenue by offering our platform as a drug screening service to other biotech companies.

H7 Biocapital